Volume 30, Number 3—March 2024
Synopsis
Concurrent Clade I and Clade II Monkeypox Virus Circulation, Cameroon, 1979–2022
Delia D. Djuicy, Serge A. Sadeuh-Mba1, Chanceline N. Bilounga, Martial G. Yonga, Jules B. Tchatchueng-Mbougua, Gael D. Essima, Linda Esso, Inès M.E. Nguidjol, Steve F. Metomb, Cornelius Chebo, Samuel M. Agwe, Placide A. Ankone, Firmin N.N. Ngonla, Hans M. Mossi, Alain G.M. Etoundi, Sara I. Eyangoh, Mirdad Kazanji, and Richard Njouom
Table 2
Clinical Characteristics of suspected and confirmed mpox cases in a study of concurrent clade I and clade II monkeypox virus circulation, Cameroon, 1979–2022*
| Characteristics |
MPXV RT-PCR, no. (%) |
Crude OR (95% CI) |
p value |
|
|---|---|---|---|---|
| Positive |
Negative |
|||
| Total no. (%), n = 137 |
32 (23.36) |
105 (76.64) |
||
| Active skin lesions | ||||
| Lesions, n = 124 | 29 (23.39) | 95 (76.61) | Referent | 0.289 |
| No lesions, n = 10 |
1 (10.00) |
9 (90.00) |
2.75 (0.33–22.6) |
|
| Lesion progress | ||||
| Diffuse, n = 23 | 5 (21.74) | 18 (78.26) | Referent | 0.329 |
| Head to limbs, n = 25 | 4 (16.00) | 21 (84.00) | 0.69 (0.16–2.95) | |
| Limbs to head, n = 15 | 6 (40.00) | 9 (60.00) | 2.4 (0.57–10.04) | |
| Others, n = 24 |
4 (16.67) |
20 (83.33) |
0.72 (0.17–3.1) |
|
| Lesions at the same stage | ||||
| Y, n = 43 | 13 (30.23) | 30 (69.77) | Referent | 0.195 |
| N, n = 53 |
10 (18.87) |
43 (81.13) |
1.86 (0.72–4.8) |
|
| Lesions of the same size | ||||
| Y, n = 49 | 13 (26.53) | 36 (73.47) | Referent | 0.546 |
| N, n = 47 |
10 (21.28) |
37 (78.72) |
1.34 (0.52–3.43) |
|
| Lesions deep | ||||
| Y, n = 42 | 11 (26.19) | 31 (73.81) | Referent | 0.767 |
| N, n = 51 |
12 (23.53) |
39 (76.47) |
1.15 (0.45–2.97) |
|
| Fever before rash | ||||
| Y, n = 86 | 22 (25.58) | 64 (74.42) | Referent | 0.149 |
| N, n = 30 | 4 (13.33) | 26 (86.67) | 2.23 (0.7–7.12) | |
| Missing |
6 |
15 |
NA |
|
| Headache | ||||
| Y, n = 51 | 15 (29.41) | 36 (70.59) | Referent | 0.1 |
| N, n = 61 |
10 (16.39) |
51 (83.61) |
2.13 (0.86–5.26) |
|
| Cough | ||||
| Y, n = 38 | 13 (34.21) | 25 (65.79) | Referent | 0.066 |
| N, n = 76 |
14 (18.42) |
62 (81.58) |
2.3 (0.95–5.59) |
|
| Vomiting, nausea | ||||
| Y, n = 15 | 4 (26.67) | 11 (73.33) | Referent | 0.722 |
| N, n = 98 |
22 (22.45) |
76 (77.55) |
1.26 (0.36–4.34) |
|
| Chills, sweat | ||||
| Y, n = 48 | 18 (37.50) | 30 (62.50) | Referent | 0.003 |
| N, n = 66 |
9 (13.34) |
57 (86.36) |
3.8 (1.52–9.48) |
|
| Lymphadenopathy | ||||
| Y, n = 29 | 12 (41.38) | 17 (58.62) | Referent | 0.009 |
| N, n =84 |
14 (16.37) |
70 (83.33) |
3.53 (1.38–9.00) |
|
| Sore throat when swallowing | ||||
| Y, n = 28 | 16 (51.14) | 12 (42.86) | Referent | <0.001 |
| N, n = 85 |
10 (11.76) |
75 (88.24) |
10 (3.69–27.12) |
|
| Oral ulcer | ||||
| Y, n = 18 | 11 (61.11) | 7 (38.89) | Referent | <0.001 |
| N, n = 95 |
15 (15.79) |
80 (84.21) |
8.38 (2.80–25.09) |
|
| Itchy lesions | ||||
| Y, n = 75 | 19 (25.33) | 56 (74.67) | Referent | 0.397 |
| N, n = 43 | 8 (18.60) | 35 (81.40) | 1.48 (0.59–3.75) | |
| Unknown |
5 |
14 |
NA |
|
| General fatigue | ||||
| Y, n = 62 | 20 (32.25) | 42 (67.74) | Referent | 0.016 |
| N, n = 52 |
7 (13.46) |
45 (86.54) |
3.06 (1.17–7.98) |
|
| Myalgia | ||||
| Y, n = 29 | 9 (31.03) | 20 (68.97) | Referent | 0.244 |
| N, n = 84 | 17 (20.24) | 67 (79.76) | 1.77 (0.69–4.59) | |
| Unknown |
6 |
18 |
NA |
|
| Conjunctivitis | ||||
| Y, n = 14 | 2 (14.29) | 12 (85.71) | Referent | 0.385 |
| N, n = 99 | 24 (24.24) | 75 (75.76) | 0.52 (0.11–2.49) | |
*Bold text indicates statistical significance. Missing data is for patients who did not provide an answer. Unknown is for persons who replied that they did not know. Some categories might not add to 100% because of missing data. Missing data were not accounted for in the statistical analysis. MPXV, monkeypox virus; NA, not applicable; OR, odds ratio.
1Current affiliation: Maryland Department of Agriculture, Salisbury, Maryland, USA.
Page created: January 18, 2024
Page updated: February 22, 2024
Page reviewed: February 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.